PolyActiva Raises AUD$9.2M in Series B Financing

PolyActiva, a Melbourne, Australia-based  biotechnology company, raised AUD $9.2m in Series B financing.

Backers included the Medical Research Commercialisation Fund (MRCF) and Brandon Biosciences Fund 1 (BBF1) (both managed by Brandon Capital), Yuuwa Capital and angel investors.

founded in 2011 and led by Dr Russell Tait, CEO, PolyActiva has developed proprietary drug-polymer conjugate technology that enables site-specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers.

The company intends to use the capital to further the preclinical and clinical development programs of its products under development, including an intra-ocular implant to treat glaucoma, an intra-ocular implant to treat severe infections of the eye and an intra-articular product to treat osteoarthritis.



Join the discussion